Compare LWAY & CMPX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LWAY | CMPX |
|---|---|---|
| Founded | 1986 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 474.0M | 408.8M |
| IPO Year | 1995 | 2020 |
| Metric | LWAY | CMPX |
|---|---|---|
| Price | $30.78 | $2.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 9 |
| Target Price | ★ $34.50 | $14.57 |
| AVG Volume (30 Days) | 181.0K | ★ 2.6M |
| Earning Date | 05-14-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 48.33 | N/A |
| EPS | ★ 0.30 | N/A |
| Revenue | ★ $103,350,000.00 | N/A |
| Revenue This Year | $16.64 | N/A |
| Revenue Next Year | $17.28 | $934.41 |
| P/E Ratio | $101.10 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $17.31 | $1.61 |
| 52 Week High | $34.20 | $6.88 |
| Indicator | LWAY | CMPX |
|---|---|---|
| Relative Strength Index (RSI) | 57.65 | 44.68 |
| Support Level | $22.03 | $1.88 |
| Resistance Level | $31.23 | $2.14 |
| Average True Range (ATR) | 1.35 | 0.11 |
| MACD | -0.29 | -0.01 |
| Stochastic Oscillator | 58.21 | 25.68 |
Lifeway Foods Inc is engaged in manufacturing probiotic, cultured, functional dairy health food products. Its primary product is drinkable kefir, which is a cultured dairy product. Its product categories are Drinkable Kefir, which is the key revenue-driving product, European-style soft cheeses, Cream, ProBugs, Frozen Kefir, and Other dairy. The company manufactures and markets products under the Lifeway and Fresh Made brand names, as well as under private labels on behalf of customers. It sells the products through a direct sales force, brokers, and distributors.
Compass Therapeutics Inc is a clinical-stage oncology-focused biopharmaceutical company that develops proprietary antibody therapeutics to engage the immune system to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth. It is engaged in drug discovery by leveraging its proprietary antibody discovery engine to target the immune system and identify optimal combinations empirically broadly. Through StitchMabs and common light chain platforms, these combinatorial insights can be rapidly translated into tailored bispecifics with monoclonal-like manufacturability. Its pipeline is comprised of the following product candidates; CTX-009, CTX-471, CTX-10726, VEGF-A, Bispecific, and CTX-8371.